Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in nAMD (LUCERNE)
NCT03823300Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of faricimab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Roche. Primary endpoint: Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Weeks 40, 44, and 48 at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03823300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823300.